Equities researchers at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.
Bio-Path Stock Performance
NASDAQ BPTH opened at $0.82 on Friday. The stock’s 50 day simple moving average is $0.97 and its 200 day simple moving average is $1.51. Bio-Path has a one year low of $0.61 and a one year high of $12.37.
Hedge Funds Weigh In On Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new position in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path at the end of the most recent reporting period. 5.74% of the stock is currently owned by institutional investors.
Bio-Path Company Profile
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Read More
- Five stocks we like better than Bio-Path
- The How and Why of Investing in Gold Stocks
- Vertiv’s Cool Tech Makes Its Stock Red-Hot
- Industrial Products Stocks Investing
- MarketBeat Week in Review – 11/18 – 11/22
- 3 Healthcare Dividend Stocks to Buy
- 2 Finance Stocks With Competitive Advantages You Can’t Ignore
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
